A comprehensive analysis of SOX17 expression by immunohistochemistry in human epithelial tumors, with an emphasis on gynecologic tumors
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae104 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Beth Z Clark und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Pittsburgh School of Medicine, UPMC Magee-Womens Hospital, Pittsburgh, PA, US. Hauptthemen laut MEDLINE: SOXF Transcription Factors, Biomarkers, Tumor, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objectives
The objective of this study was to evaluate SOX17, a transcription factor from the Sry high-mobility group–related box superfamily, as a diagnostic marker to determine site of origin using both whole-tissue sections and tissue microarrays (TMAs).
Methods
SOX17 immunohistochemistry was performed on gynecologic and nongynecologic tissues (N = 1004) using whole-tissue sections and both internally constructed and commercially available TMAs. SOX17 nuclear reactivity was scored as positive or negative on the whole-tissue sections and using the semiquantitative H score method on TMAs.
Results
Using both whole-tissue sections and TMAs, SOX17 was positive in 94% (n = 155) of endometrial tumors and 96% (n = 242) of ovarian tumors. All breast cases (n = 241) and vulvar/cervical squamous cell carcinomas (n = 150) were negative. Among 1004 tumors from 20 sites, the only organs with positive tumors were ovary, uterus, and testis.
Conclusions
SOX17 is a sensitive and specific marker for gynecologic origin in the tissues tested and may be a valuable adjunct to PAX8 and other commonly used markers to confirm endometrial or ovarian origin. SOX17 expression is lower in mucinous tumors, endocervical adenocarcinoma, high-grade neuroendocrine tumors, and undifferentiated/dedifferentiated endometrial carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Pittsburgh School of Medicine, UPMC Magee-Womens Hospital, Pittsburgh, PA, US.
ORCID-Profile: Beth Z Clark, Jeffrey L Fine, Jing Yu, Rohit Bhargava
Zitieren
APA
Clark, B. Z., Soong, T. R., Goel, K., Elishaev, E., Zhao, C., Jones, T. E., Jones, M. W., Skvarca, L. B., Motanagh, S. A., Carter, G. J., Fine, J. L., Harinath, L., Villatoro, T. M., Yu, J., & Bhargava, R. (2025). A comprehensive analysis of SOX17 expression by immunohistochemistry in human epithelial tumors, with an emphasis on gynecologic tumors. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae104
Vancouver
Clark BZ, Soong TR, Goel K, Elishaev E, Zhao C, Jones TE, et al. A comprehensive analysis of SOX17 expression by immunohistochemistry in human epithelial tumors, with an emphasis on gynecologic tumors. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae104
BibTeX
@article{Clark2025,
author = {Clark, Beth Z and Soong, T Rinda and Goel, Kanika and Elishaev, Esther and Zhao, Chengquan and Jones, Terri E and Jones, Mirka W and Skvarca, Lauren B and Motanagh, Samaneh A and Carter, Gloria J and Fine, Jeffrey L and Harinath, Lakshmi and Villatoro, Tatiana M and Yu, Jing and Bhargava, Rohit},
title = {A comprehensive analysis of SOX17 expression by immunohistochemistry in human epithelial tumors, with an emphasis on gynecologic tumors},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae104}
}
EUVIMED